Breaking News Instant updates and real-time market news.

DIS

Disney

$112.72

0.9647 (0.86%)

, SFM

Sprouts Farmers Market

$21.82

-0.2 (-0.91%)

16:15
03/20/17
03/20
16:15
03/20/17
16:15

On The Fly: Top stock stories for Monday

The major averages started the day with a quiet opening, previewing the type of session it would be as they spent the rest of the trading day in a narrow range drifting near the unchanged line. ECONOMIC EVENTS: In the U.S., the Chicago National Activity index rose to 0.34 in February after dipping to -0.02 in January. In Europe, the U.K. said it will formally trigger its exit from the EU on March 29. Triggering Article 50 of the Lisbon Treaty, the formal procedure for leaving the bloc, will open a two-year timetable for negotiations, with Britain able to leave the EU by 2019. COMPANY NEWS: Walt Disney's (DIS) "Beauty and the Beast," the latest in a string of live-action remakes of animated classics from the company, topped box offices with a $170M launch in the U.S. alongside $180M from international markets. Shares of Disney gained 0.85% to $112.71 after the film's record-breaking debut... Shares of Sprout Farmers Market (SFM), which jumped about 25% last week, ended the day down about 0.9% at $21.83 after Bloomberg reported that Cerberus Capital-backed Albertsons has held preliminary merger talks with the company. Shares of its larger competitor Whole Foods Market (WFM) gained about 1% following the news... Snap Inc. (SNAP) landed its first Buy rating since coming public, as Monness Crespi analyst James Cakmak initiated the stock and said he is prepared to "give the benefit of the doubt" to the parent of Snapchat. The shares advanced 2% after Cakmak offered the opinion that "Snap could conceivably replace the camera app" on people's phones. MAJOR MOVERS: Among the notable gainers was Nektar Therapeutics (NKTR), which advanced over 42% after the company said that a late-stage trial of NKTR-181, which was previously granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of moderate to severe chronic pain, met the primary and secondary endpoints. Also higher was CytomX Therapeutics (CTMX), which gained 24% after announcing an expansion of the company's strategic collaboration with Bristol-Myers Squibb (BMY). Additionally, Esperion Therapeutics (ESPR) jumped 74% after the biotech company announced that the Food and Drug Administration gave feedback on its cholesterol-lowering drug, saying the bempedoic acid Phase 3 program is adequate to support approval of an LDL-C lowering indication prior to outcomes data. Among the noteworthy losers was Array Biopharma (ARRY), which fell nearly 5% after the company withdrew its FDA application for binimetinib in a rare subset of skin cancer. Also lower was Sonic (SONC), which slipped 3% Canaccord analyst Lynne Collier downgraded the stock to Hold, citing challenging industry sales, the potential for Street estimates to be too high in the midst of soft sales, a lack of upcoming catalysts, and increasing competition from non-traditional venues such as convenience stores. INDEXES: The Dow slipped 8.76, or 0.04%, to 20,905.86, the Nasdaq gained 0.53, or 0.01%, to 5,901.53, and the S&P 500 declined 4.78, or 0.2%, to 2,373.47.

DIS

Disney

$112.72

0.9647 (0.86%)

SFM

Sprouts Farmers Market

$21.82

-0.2 (-0.91%)

WFM

Whole Foods

$29.85

0.32 (1.08%)

SNAP

Snap

$19.84

0.3 (1.54%)

NKTR

Nektar

$22.10

6.6 (42.58%)

CTMX

CytomX Therapeutics

$18.89

3.71 (24.44%)

BMY

Bristol-Myers

$56.42

0.13 (0.23%)

ARRY

Array BioPharma

$10.07

-0.49 (-4.64%)

SONC

Sonic

$23.08

-0.7 (-2.94%)

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 29

    Mar

  • 01

    Apr

  • 27

    Apr

  • 20

    Jun

  • 30

    Jun

DIS Disney
$112.72

0.9647 (0.86%)

03/16/17
PIPR
03/16/17
NO CHANGE
Target $130
PIPR
Overweight
Piper more confident after seeing Disney's Beauty and the Beast
Piper Jaffray analyst Stan Meyers says he left a screening of Disney's Beauty and the Beast more confident in his $900M global box office forecast. The analyst admits the film's 68% Rotten Tomatoes score is an issue, but he believes limited competition over the next few weeks and the film's darker undertone to broaden the target audience should secure "strong staying power" after the opening. He expects the movie to open in the $130M-$140M range. Meyers keeps an Outperform rating on Disney.
03/14/17
03/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris upgraded saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118. 2. Dick's Sporting (DKS) upgraded to Outperform from Peer Perform at Wolfe Research. 3. Quest Diagnostics (DGX) upgraded to Conviction Buy from Buy at Goldman with analyst Isaac Ro saying the company should be a key beneficiary as the U.S. healthcare system shifts the cost burden to the individual and creates price transparency for the first time. 4. Olympic Steel (ZEUS) and Reliance Steel (RS) were upgraded to Outperform from Neutral at Macquarie, while Worthington (WOR) was upgraded to Neutral from Underperform. 5. Ethan Allen (ETH) upgraded to Strong Buy from Market Perform at Raymond James with analyst Budd Bugatch double upgrading the company saying sales comparisons get easier through 2017 while the retailer's remerchandising effort is behind it, thereby lowering the clearance markdowns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/17
GUGG
03/14/17
UPGRADE
Target $128
GUGG
Buy
Disney upgraded to Buy from Neutral at Guggenheim
Guggenheim analyst Michael Morris upgraded Disney to Buy from Neutral saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118.
03/20/17
PIPR
03/20/17
NO CHANGE
Target $130
PIPR
Overweight
Disney's Beauty and the Beast topped expectations, says Piper Jaffray
Piper Jaffray analyst Stan Meyers says Disney's Beauty and the Beast topped expectations this weekend with a domestic opening of $170M, ahead of his $130M-$140M estimate and industry tracking of $125M. He now expects the film to cross the $450M mark domestically, ahead of his $400M estimate. Meyers remains a buyer of Disney shares with an Overweight rating and $130 price target.
SFM Sprouts Farmers Market
$21.82

-0.2 (-0.91%)

02/27/17
RBCM
02/27/17
NO CHANGE
RBCM
Sprouts Farmers Markets fiscal 2017 guidance conservative, says RBC Capital
After Sprouts reported stronger than expected results, RBC Capital analyst William Kirk says that the company's fundamentals continue to be strong. He thinks that the company's guidance is "beatable," partly due to easing comps and lessening cannibalization, along with the contribution of the company's new stores to comp increases. Kirk remains upbeat on the company's fundamentals and keeps an Outperform rating on the shares.
03/20/17
JEFF
03/20/17
NO CHANGE
Target $22
JEFF
Buy
Jefferies sees $26/share buyout price for Sprouts Farmers Market
After Bloomberg reported that Cerberus Capital Management-backed Albertsons held preliminary talks to merge with Sprouts Farmers Market, Jefferies analyst Christopher Mandeville says historical transactions suggest a $26 per share takeout price for Sprouts. The stock in pre-market trading is up 5%, or $1.13, to $23.15. If Sprouts is willing to sell itself, multiple suitors, both financial and strategic, could show interest, leading to a competitive bidding process that could potentially push the valuation higher than $26 per share, Mandeville tells investors in a research note. The company, as one of the last few growth concepts remaining in grocery, should "receive a very healthy valuation," the analyst argues. He has a Buy rating on Sprouts with a $22 price target.
02/01/17
OTRG
02/01/17
UPGRADE
OTRG
Mixed
Sprouts Farmers Markets upgraded to Mixed from Negative at OTR Global
OTR Global changed its view on Sprouts Farmers Markets to Mixed following checks that indicate orders improved slightly in Q4 due to promotions.
02/02/17
FBCO
02/02/17
NO CHANGE
Target $23
FBCO
Outperform
Re-inflation to alleviate Sprouts Farmers Markets pressure, says Credit Suisse
Credit Suisse analyst Edward Kelly says that while short-term caution is certainly warranted given accelerating produce deflation and a tough overall competitive environment, he thinks Sprouts Farmers Markets' Q4 will eventually result in an attractive opportunity. The analyst believes the stock may be the most leveraged to re-inflation at this point, as comps should see relief when pricing firms, margin pressure should moderate as industry promotions begin to ease, and the valuation has upside given it is likely to remain a growth story. He reiterates an Outperform rating and $23 price target on the shares.
WFM Whole Foods
$29.85

0.32 (1.08%)

02/09/17
FBCO
02/09/17
NO CHANGE
Target $36
FBCO
Outperform
Whole Foods price target lowered to $36 from $40 at Credit Suisse
Credit Suisse analyst Edward Kelly lowered his price target for Whole Foods to $36 from $40 following the company's mixed Q1 earnings update. The analyst reiterates an Outperform rating on the shares as he continues to see value in the brand, believes there is a path for improved performance over time, and likes the stock's risk/reward.
01/20/17
01/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Aegis. 2. Alphabet (GOOG, GOOGL) and Facebook (FB) were resumed with an Overweight at Pacific Crest, while Twitter (TWTR) was resumed with a Sector Weight. 3. Costco (COST) coverage was resumed with a Buy at Stifel, while Wal-Mart (WMT) and Target (TGT) were resumed with a Hold. 4. Whole Foods (WFM) was initiated with a Market Perform, while Sprouts Farmers Markets (SFM) was initiated with an Outperform at William Blair. 5. CBS (CBS) was reinstated with an Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/02/17
CLVD
02/02/17
NO CHANGE
CLVD
Whole Foods estimate lowered on softenting trends at Cleveland Research
02/09/17
PIVT
02/09/17
NO CHANGE
Target $20
PIVT
Sell
Pivotal calls Whole Foods sales deceleration 'alarming'
Pivotal Research analyst Ajay Jain believes Whole Foods' sales are decelerating at an "alarming rate." The company's guidance reduction last night is the latest in a multi-year string of earnings setbacks, Jain tells investors in a post-earnings research note. He keeps a Sell rating on the shares with a $20 price target.
SNAP Snap
$19.84

0.3 (1.54%)

03/17/17
MZHO
03/17/17
INITIATION
Target $20
MZHO
Neutral
Snap initiated with a Neutral at Mizuho
Mizuho analyst Neil Doshi started Snap Inc. with a Neutral rating and $20 price target.
03/17/17
03/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with an Outperform at Bernstein. 2. Snap (SNAP) initiated with a Neutral at Mizuho. 3. Cantel Medical (CMD) initiated with a Market Perform at Raymond James. 4. Hilton (HLT) reinstated with an Overweight at JPMorgan. 5. Regeneron (REGN) initiated with a Perform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/17
MONN
03/20/17
INITIATION
Target $25
MONN
Buy
Snap initiated with a Buy at Monness Crespi
Monness Crespi analyst James Cakmak initiated Snap with a Buy and a $25 price target.
03/20/17
03/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Monness Crespi analyst James Cakmak initiated Snap (SNAP) with a Buy and a $25 price target. 2. Workday (WDAY) initiated with a Buy at BofA/Merrill. 3. Berkshire Hathaway (BRK.A) initiated with an Equal Weight at Morgan Stanley. 4. MeetMe (MEET) initiated with a Buy at Canaccord. 5. ARC Document (ARC) resumed with a Buy at B. Riley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NKTR Nektar
$22.10

6.6 (42.58%)

01/06/17
BTIG
01/06/17
INITIATION
Target $22
BTIG
Buy
Nektar initiated with a Buy at BTIG
BTIG analyst Robert Hazlett started Nektar Therapeutics with a Buy rating and $22 price target. Several "intriguing" emerging therapeutics along with multiple near-term catalysts make the shares attractive, Hazlett tells investors in a research note.
01/26/17
PIPR
01/26/17
NO CHANGE
PIPR
Overweight
Celgene acquisition highlights underappreciated Nektar asset, says Piper Jaffray
After Celgene (CELG) announced this morning a deal to acquire Delinia for $300M plus up to $475M in potential milestones, Piper Jaffray analyst Joshua Schimmer noted that the company's lead asset, DEL106, being developed for autoimmune disorders, is similar to Nektar's (NKTR) NKTR-358. While many investors are familiar with Nektar's immune-oncology program, NKTR-214, far fewer are familiar with NKTR-358, though both represent potential blockbuster opportunities if successful, Schimmer tells investors. He keeps an Overweight rating on Nektar, which he identifies as one of his top mid-cap picks.
03/20/17
PIPR
03/20/17
NO CHANGE
Target $29
PIPR
Overweight
Nektar price target raised to $29 after opioid trial success at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he thought prospects of success for NKTR-181 were very low after a failed Phase 2 study but he was "happy to be proven wrong" after the SUMMIT trial succeeded. A human abuse liability study will read-out around mid-2017, after which the company will meet with the FDA to discuss whether the package for NKTR-181 is adequate for filing, Schimmer noted. He raised his price target on Nektar shares to $29 from $25 and keeps an Overweight rating on the stock, which he calls his "top mid-cap biotech stocks for other reasons," such as its multiple royalty streams from partnered products and its emerging immuno-oncology platform.
03/20/17
ROTH
03/20/17
NO CHANGE
Target $31
ROTH
Buy
Roth Capital raises Nektar price target to $31 after 'impressive' opioid data
Roth Capital analyst Michael Higgins called Nektar's Phase 3 results for NKTR-181 "impressive" and said he expect management will now enter into negotiations to out-license the drug while meeting with the FDA. Higgins, who believes the drug is worth $2B by "conservatively" estimating its value at 3-4X peak sales, raised his price target on Nektar shares to $31 from $23 and reiterates a Buy rating on the stock.
CTMX CytomX Therapeutics
$18.89

3.71 (24.44%)

03/20/17
BOFA
03/20/17
NO CHANGE
Target $28
BOFA
Buy
CytomX Therapeutics price target raised to $28 from $23 at BofA/Merrill
BofA/Merrill raised CytomX Therapeutics' (CTMX) price target to $28 to reflect expansion of the Bristol-Myers (BMY) collaboration and payments.
03/20/17
NOMU
03/20/17
NO CHANGE
Target $32
NOMU
Buy
CytomX Therapeutics price target raised to $32 from $21 at Nomura
01/03/17
OPCO
01/03/17
DOWNGRADE
OPCO
Perform
CytomX Therapeutics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann downgraded CytomX Therapeutics to Perform citing valuation. The analyst's model assumes only one of the company's experimental therapies has a revenue impact between 2016 and 2025.
03/01/17
NOMU
03/01/17
INITIATION
Target $21
NOMU
Buy
CytomX Therapeutics initiated with a Buy at Nomura
Nomura initiated CytomX Therapeutics with a Buy and a $21 price target.
BMY Bristol-Myers
$56.42

0.13 (0.23%)

03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
02/01/17
GSCO
02/01/17
NO CHANGE
GSCO
Bristol-Myers estimates trimmed for Sprycel loss at Goldman
Goldman reduced Bristol-Myers earnings estimates by 4c-7c for 2017-2021 to reflect the lost of the Sprycel appeal in the EU. The firm continues to rate Bristol-Myers a Buy.
02/15/17
DBAB
02/15/17
NO CHANGE
DBAB
Deutsche not seeing Pfizer buying Bristol-Myers at this time
Following yesterday's speculation of a potential deal, Deutsche Bank analyst Gregg Gilbert said he would be surprised to see Pfizer (PFE) make a move on Bristol-Myers Squibb (BMY) at this stage. Such an acquisition "would represent a very large and concentrated opportunity/risk on immuno-oncology, an area fraught with near-term uncertainty," Gilbert told investors last night in a research note. He believes that if Pfizer were to use $90B for a deal, it would prefer to acquire a more diverse set of value drivers. The analyst keeps a Hold rating on Bristol and Buy rating on Pfizer. Bristol shares rose 3% yesterday to $53.71 amid speculation of a potential takeover. The conjecture had Roche (RHHBY), Novartis (NVS) and Pfizer potentially looking into a bid for Bristol.
03/06/17
FBCO
03/06/17
NO CHANGE
FBCO
Near-Term acquisition of Bristol-Myers unlikely, says Credit Suisse
Credit Suisse analyst Vamil Divan says there is increasing investor focus on strategic actions and opportunities around Bristol-Myers (BMY) following the company's recent stumbles and the increased stake activist investors have taken in the stock. The analyst notes that "the big question" remains whether any of its peers may be interested in an outright acquisition, with Pfizer (PFE), Novartis (NVS) and Gilead (GILD) among the possible acquirers. While the numbers may make sense, Divan sees an acquisition in the next 9-12 months as unlikely as he needs more clarity on some of the large unknowns in the lung cancer market and macro issues such as corporate tax reform.
ARRY Array BioPharma
$10.07

-0.49 (-4.64%)

03/20/17
LEER
03/20/17
NO CHANGE
Target $9
LEER
Market Perform
Binimetinib NDA withdrawal 'a clear setback' for Array BioPharma, says Leerink
Leerink analyst Michael Schmidt notes that Array BioPharma announced it has withdrawn its new drug application for binimetinib in NRAS+ melanoma following recent FDA interactions since results of the Phase 3 trial do not support regulatory approval. While NRAS+ melanoma was only a small value driver for the company, the analyst thinks this comes as a surprise to investors and is "a clear setback" for Array and management's regulatory and commercial strategy. He reiterated a Market Perform rating on the stock, and lowered his price target on the shares to $9 from $11.
03/20/17
JPMS
03/20/17
NO CHANGE
Target $9
JPMS
Neutral
JPMorgan sees Array down 5%-10% on withdrawal news
JPMorgan analyst Anupam Rama says Array BioPharma's withdrawal of its new drug application filing for binimetinib in NRAS melanoma is a surprise. The analyst lowered his price target for the shares to $9 from $10 and thinks the stock today could be down 5%-10%. The analyst notes that NRAS melanoma only contributed around $100M in peak sales and $1 per share to his model. Rama keeps a Neutral rating on Array. The stock in premarket trading is down 14%, or $1.41, to $9.15.
03/20/17
COWN
03/20/17
NO CHANGE
Target $14
COWN
Outperform
Array BioPharma weakness a buying opportunity, says Cowen
Cowen analyst Chris Shibutani said Array's decision to withdraw its application for binimetinib monotherapy for the treatment of NRAS-mutant melanoma was prudent given the known modest efficacy benefit. He views the decision as a de-risking event and said weakness in the shares is a buying opportunity. Shibutani reiterated his Outperform rating and lowered his price target to $14 from $15 on Array Biopharma shares.
03/20/17
WELS
03/20/17
NO CHANGE
WELS
Array chances in BRAF not impacted by NRAS melanoma withdrawal, says Wells Fargo
After Array BioPharma withdrew its application for FDA approval of its binimetinib drug as an NRAS mutant melanoma treatment following a meeting with the agency, Wells Fargo does not think the withdrawal impacts the chances of the drug succeeding as a treatment for BRAF melanoma. Wells says that the BRAF indication is larger, while the benefit of the drug is also greater in that indication and it appears to be best in class. Wells trimmed its price target on Array to $13-$15 from $16-$18 but keeps an Outperform rating on the shares.
SONC Sonic
$23.08

-0.7 (-2.94%)

12/14/16
12/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dunkin' Brands (DNKN) initiated with a Market Perform at Cowen. 2. Sonic (SONC) initiated with a Market Perform at Cowen. 3. Advance Auto Parts (AAP) was initiated with an Overweight at Atlantic Equities while the firm initiated AutoZone (AZO), Genuine Parts (GPC), and O'Reilly Automotive (ORLY) with a Neutral. 4. Blackhawk (HAWK) initiated with a Buy at Craig-Hallum. 5. Evercore Partners (EVR) initiated with a Neutral at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/16/16
MSCN
12/16/16
INITIATION
MSCN
Sonic coverage initiated at MScience
03/20/17
03/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pivotal Research analyst Brian Wieser downgraded Alphabet (GOOGL) to Hold from Buy citing brand safety concerns and valuation following the recent rally in the shares. News last week that Havas, the sixth largest global media network, is pulling its spending from Google's YouTube and Google Display Network in the U.K. because Google was "unable to provide specific reassurances, policy and guarantees that their video or display content is classified either quickly enough or with the correct filters" is a big deal, Wieser tells investors. 2. Canaccord analyst Lynne Collier downgraded Sonic (SONC) to Hold from Buy, citing challenging industry sales, the potential for Street estimates to be too high in the midst of soft sales, a lack of upcoming catalysts, and increasing competition from non-traditional venues such as convenience stores. 3. Piper Jaffray analyst Alexander Potter downgraded Mobileye (MBLY) to Neutral saying that while demanding a higher buyout price may be justified, he "begrudgingly" concluded that the price Intel (INTC) is paying for the company is fair. The analyst raised his price target for Mobileye shares to $63.54 from $60 to reflect Intel's offer. 4. Susquehanna analyst Sam Poser downgraded Caleres (CAL) citing the company's "disappointing" results and his belief that the company will not be able to overcome industry headwinds. 5. Goldman Sachs analyst Conor Fitzgerald downgraded Stifel Financial (SF) to Neutral from Buy while raising his price target for the shares to $59 from $58. The analyst believes LPL Financial (LPLA), a stock he upgraded this morning to Conviction Buy, offers more upside at current valuations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/17
ADAM
03/20/17
DOWNGRADE
Target $24
ADAM
Hold
Sonic downgraded to Hold at Canaccord
As reported previously, Canaccord analyst Lynne Collier downgraded Sonic to Hold from Buy. Collier cited challenging industry sales, the potential for Street estimates to be too high in the midst of soft sales, a lack of upcoming catalysts, and increasing competition from non-traditional venues such as convenience stores. Collier lowered her price target to $24 from $30 on Sonic shares.

TODAY'S FREE FLY STORIES

06:05
05/29/17
05/29
06:05
05/29/17
06:05
General news
WTI crude futures are off by 0.2% »

WTI crude futures are off…

03:10
05/29/17
05/29
03:10
05/29/17
03:10
General news
FX Update: The dollar majors have been plying narrow ranges »

FX Update: The dollar…

03:05
05/29/17
05/29
03:05
05/29/17
03:05
General news
Fed's Williams: three hikes this year still make sense. »

Fed's Williams:…

RBGLY

Reckitt Benckiser

$20.53

0.04 (0.20%)

, MJN

Mead Johnson

$89.29

0.1 (0.11%)

15:32
05/28/17
05/28
15:32
05/28/17
15:32
Conference/Events
Mead Johnson to host special shareholder meeting »

Special Shareholder…

RBGLY

Reckitt Benckiser

$20.53

0.04 (0.20%)

MJN

Mead Johnson

$89.29

0.1 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

PHH

PHH Corp.

$13.58

0.06 (0.44%)

15:25
05/28/17
05/28
15:25
05/28/17
15:25
Conference/Events
PHH Corp. to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

TPIV

TapImmune

$3.71

-0.03 (-0.80%)

14:37
05/28/17
05/28
14:37
05/28/17
14:37
Conference/Events
TapImmune to hold a business update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SCOR

comScore

$24.80

-0.15 (-0.60%)

14:35
05/28/17
05/28
14:35
05/28/17
14:35
Conference/Events
comScore to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BMY

Bristol-Myers

$53.97

-0.42 (-0.77%)

14:12
05/28/17
05/28
14:12
05/28/17
14:12
Conference/Events
Bristol-Myers to hold a pharmaceutical update conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 04

    Jun

  • 06

    Jun

  • 24

    Sep

LOXO

Loxo Oncology

$47.44

-0.06 (-0.13%)

14:10
05/28/17
05/28
14:10
05/28/17
14:10
Conference/Events
Loxo Oncology to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 04

    Jun

  • 06

    Jun

ADRO

Aduro Biotech

$10.05

-0.15 (-1.47%)

14:07
05/28/17
05/28
14:07
05/28/17
14:07
Conference/Events
Aduro Biotech to host analyst and investor meeting »

Management hosts special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

ELGX

Endologix

$4.73

-0.05 (-1.05%)

14:06
05/28/17
05/28
14:06
05/28/17
14:06
Conference/Events
Endologix to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 31

    May

  • 03

    Jun

TSRO

Tesaro

$149.11

-4.08 (-2.66%)

14:02
05/28/17
05/28
14:02
05/28/17
14:02
Conference/Events
Tesaro to hold an analyst and investor briefing »

Management hosts an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 03

    Jun

  • 30

    Jun

ICE

IntercontinentalExchange

$60.35

-0.09 (-0.15%)

13:57
05/28/17
05/28
13:57
05/28/17
13:57
Conference/Events
IntercontinentalExchange to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 07

    Jun

CPA

Copa Holdings

$111.69

0.2 (0.18%)

13:48
05/28/17
05/28
13:48
05/28/17
13:48
Conference/Events
Copa Holdings to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

CAH

Cardinal Health

$73.10

-0.34 (-0.46%)

13:31
05/28/17
05/28
13:31
05/28/17
13:31
Conference/Events
Cardinal Health to hold a meeting »

Dublin Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

BPMX

BioPharmX

$0.64

0.0089 (1.41%)

13:26
05/28/17
05/28
13:26
05/28/17
13:26
Conference/Events
BioPharmX holds state of acne symposium »

Management provides…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$80.63

-0.72 (-0.89%)

13:20
05/28/17
05/28
13:20
05/28/17
13:20
Conference/Events
Novartis to hold a meeting »

Meet the Management Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 26

    Jun

CNC

Centene

$74.57

-0.68 (-0.90%)

, MOH

Molina Healthcare

$66.87

-0.21 (-0.31%)

12:34
05/27/17
05/27
12:34
05/27/17
12:34
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CNC

Centene

$74.57

-0.68 (-0.90%)

MOH

Molina Healthcare

$66.87

-0.21 (-0.31%)

HUM

Humana

$232.25

0.02 (0.01%)

AET

Aetna

$145.57

0.34 (0.23%)

ANTM

Anthem

$183.08

1.58 (0.87%)

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

WCG

WellCare

$172.97

0.15 (0.09%)

CI

Cigna

$161.32

-0.33 (-0.20%)

BX

Blackstone

$32.58

0.11 (0.34%)

NUE

Nucor

$58.15

-0.22 (-0.38%)

X

U.S. Steel

$19.74

-0.51 (-2.52%)

STLD

Steel Dynamics

$33.71

-0.73 (-2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

  • 16

    Jun

21:00
05/26/17
05/26
21:00
05/26/17
21:00
General news
Breaking General news story  »

San Francisco Federal…

20:00
05/26/17
05/26
20:00
05/26/17
20:00
General news
Breaking General news story  »

San Francisco Federal…

JUNO

Juno Therapeutics

$23.30

-2.22 (-8.70%)

18:11
05/26/17
05/26
18:11
05/26/17
18:11
Hot Stocks
Juno Therapeutics director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

18:06
05/26/17
05/26
18:06
05/26/17
18:06
Hot Stocks
UnitedHealth's OptumHealth awarded $200.5M government contract »

UnitedHealth's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

VEC

Vectrus

$29.62

0.02 (0.07%)

17:56
05/26/17
05/26
17:56
05/26/17
17:56
Hot Stocks
Vectrus Systems awarded $212.03M modification to government contract »

Vectrus Systems was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMY

Imprimis

$3.34

-0.06 (-1.76%)

17:52
05/26/17
05/26
17:52
05/26/17
17:52
Syndicate
Breaking Syndicate news story on Imprimis »

Imprimis files $75M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRCP

IRSA Propiedades Comerciales

$43.58

-0.33 (-0.75%)

17:51
05/26/17
05/26
17:51
05/26/17
17:51
Syndicate
Breaking Syndicate news story on IRSA Propiedades Comerciales »

IRSA Propiedades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.